Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naveed Wagle

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|February 22, 2021
Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapyMeghna Yalamanchi, Akanksha Sharma, Minh Nguyen, et al.
World Neurosurgery|February 1, 2020
Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital SettingTheodore Wang, Anthony Pham, Stella Yoo, et al.
Neuron|June 14, 2002
Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in DrosophilaGeorge R Jackson, Martina Wiedau-Pazos, Tzu-Kang Sang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 11, 2012
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspectiveFranziska Walter, Timothy Cloughesy, Martin A Walter, et al.
Journal of Neurosurgery. Case Lessons|September 11, 2022
Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative caseAxel H Schönthal, Steve Swenson, Phillip A Bonney, et al.
Clinical Imaging|June 10, 2014
Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab - recurrent tumor or atypical necrosis?Lakshmanan Sivasundaram, Saman Hazany, Naveed Wagle, et al.
Neuro-Oncology|January 25, 2012
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Timothy F Cloughesy, Taryar Zaw, et al.
Neuro-Oncology Advances|April 29, 2024
A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancerTiffany M Juarez, Jaya M Gill, Annie Heng, et al.
Journal of Neuro-Oncology|February 19, 2024
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannomaPhioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, et al.
Neuro-Oncology Advances|February 19, 2021
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastomaAxel H Schönthal, David M Peereboom, Naveed Wagle, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|February 22, 2021
Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapyMeghna Yalamanchi, Akanksha Sharma, Minh Nguyen, et al.
World Neurosurgery|February 1, 2020
Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital SettingTheodore Wang, Anthony Pham, Stella Yoo, et al.
Neuron|June 14, 2002
Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in DrosophilaGeorge R Jackson, Martina Wiedau-Pazos, Tzu-Kang Sang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 11, 2012
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspectiveFranziska Walter, Timothy Cloughesy, Martin A Walter, et al.
Journal of Neurosurgery. Case Lessons|September 11, 2022
Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative caseAxel H Schönthal, Steve Swenson, Phillip A Bonney, et al.
Clinical Imaging|June 10, 2014
Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab - recurrent tumor or atypical necrosis?Lakshmanan Sivasundaram, Saman Hazany, Naveed Wagle, et al.
Neuro-Oncology|January 25, 2012
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Timothy F Cloughesy, Taryar Zaw, et al.
Neuro-Oncology Advances|April 29, 2024
A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancerTiffany M Juarez, Jaya M Gill, Annie Heng, et al.
Journal of Neuro-Oncology|February 19, 2024
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannomaPhioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, et al.
Neuro-Oncology Advances|February 19, 2021
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastomaAxel H Schönthal, David M Peereboom, Naveed Wagle, et al.
Pageof 3